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ABSTRACT 
Objective  
To assess neurocognitive function at first-line antiretroviral therapy failure and change on second–line 
therapy   
Design  
Randomized controlled trial conducted in 5 sub-Saharan African countries. 
Methods 
Patients failing first-line therapy according to WHO criteria after >12 months on NNRTI-based regimens 
were randomised to second-line therapy (open-label) with lopinavir/ritonavir (400mg/100mg twice 
daily) plus either 2-3 clinician-selected NRTIs, raltegravir, or as monotherapy after 12 weeks induction 
with raltegravir. Neurocognitive function was tested at baseline, weeks 48 and 96 using colour trails 
tests 1 and 2, and the grooved pegboard test. Test results were converted to an average of the 3 
individual test z-scores.   
Results  
1036 patients (90% of those >18y enrolled at 13 evaluable sites) had valid baseline tests (58% female, 
median 38 years, viral load 65,000 c/ml, CD4 count 73 cells/mm3). Mean (SD) baseline z-score was -2.96 
(1.74); lower baseline z-scores were independently associated with older age, lower body weight, higher 
viral load, lower haemoglobin, less education, fewer weekly working hours, previous CNS disease, and 
taking fluconazole (P<0.05 in multivariable model). Z-score increased by mean (SE) of +1.23 (0.04) after 
96 weeks on second-line therapy (P<0.001; n=915 evaluable), with no evidence of difference between 
the treatment arms (P=0.35). 
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Conclusions 
Patients in sub-Saharan Africa failing first-line therapy had low neurocognitive function test scores, but 
performance improved on second-line therapy. Regimens with more CNS-penetrating drugs did not 
enhance neurocognitive recovery indicating this need not be a primary consideration in choosing a 
second-line regimen.  
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Introduction 
Highly-active antiretroviral therapy (HAART) improves survival and quality-of-life among HIV-infected 
individuals.1 The remarkable increase in access to HAART in resource-limited settings (RLS) over the past 
decade, as well as the current global efforts towards earlier HAART initiation, have amplified the 
benefits of HIV treatment including the impact on HIV-associated neurocognitive disorders (HAND). The 
introduction of HAART has been associated with strong reductions in prevalence of HIV-associated 
dementia (HAD)-the most severe form of HAND. However the impact of HAART on the milder forms of 
HAND including mild neurocognitive disorder (MND) and asymptomatic neurocognitive impairment 
(ANI) is less certain.2 3 MND and ANI are still common findings in HIV cohorts in the HAART era.4 5 It has 
been suggested that ART regimens including drugs with higher levels of CNS penetration might have 
greater benefit on HAND, although evidence for this is contradictory.6 7 8 9 10 The magnitude, severity 
and factors associated with HAND (including MND and ANI), as well as the response of HAND to 
antiretroviral therapy, have been fairly well characterized in resource-rich settings, but data from 
resource-limited settings (RLS) are more limited.11 12 13 RLS studies indicate that HAND is common, with 
significant regional differences in prevalence (ranging from 25%-61%),14 15 16 and has similar risk factors 
as HAD, including low CD4 counts, older age, and male gender.17 18 However, few studies have 
characterized the prevalence of neurocognitive impairment among individuals failing first-line HAART in 
either RLS or resource-rich settings, and data on neurocognitive responses on second-line therapy are 
even more limited.  
Here, we report prospective neurocognitive function measurements using a simple standardised battery 
of tests in a large multicentre trial of second-line therapy in Africa.19  
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The aim of this study was to examine the magnitude of and factors associated with neurocognitive 
impairment at the time of first-line regimen failure and assess how neurocognitive function changed 
over 96 weeks on 3 different PI based second-line regimens. 
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Methods 
The current study was conducted within the large multi-centre Europe Africa Research Network for 
Evaluation of Second-line Therapy (EARNEST) trial. Briefly, EARNEST was an open-label, randomized 
parallel-group trial (ISRCTN-37737787) performed in 14 centres in 4 sub-Saharan African countries. It 
enrolled HIV-infected patients >12 years who were failing first-line HAART (according to WHO clinical, 
immunological and/or virological criteria). Participants were randomly assigned 1:1:1 to receive a 
ritonavir-boosted protease inhibitor (PI), standardised to lopinavir/ritonavir 400mg/100mg twice daily, 
with either (i) 2-3 new or recycled nucleoside-reverse-transcriptase-inhibitors (NRTIs) chosen without 
genotyping by the treating doctor (PI/NRTI); (ii) raltegravir 400mg twice daily (PI/RAL); or (iii) raltegravir 
induction for 12 weeks only (PI-mono). Additional details including the eligibility criteria, study design 
and site settings are described elsewhere.14 
The study (including the neurocognitive assessments as part of the main trial protocol) was approved by 
ethics committees and regulatory agencies in participating countries and the UK. All participants 
provided written informed consent. 
 
 Neurocognitive assessment 
Neurocognitive function was assessed in all participants at baseline (first-line treatment failure) and at 
week 48 and week 96 using three simple neurocognitive tests, chosen to reflect frontal sub-cortical 
functions, the most common neurocognitive impairments seen in HIV-infected individuals.20 The Colour 
trails tests are two-part tests that assess the attention/concentration domain as well as the cognitive 
flexibility within the executive functioning domain21. The Grooved Pegboard test assesses psychomotor 
speed and fine motor function in both, dominant and non-dominant hands. 
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This simple battery of widely-used tests was selected to suit the clinical environments in resource-
limited settings that are often extremely busy and have no specialized neurocognitive test operators.  
The tests were administered by a clinician or research nurse. Quality assurance measures were the use 
of a standardized testing manual across all study sites, initial and annual training of site staff who were 
designated to perform the tests, restriction of test performance to the designated staff, and on-site 
monitoring of a random selection of tests to identify systematic errors in execution.  
Each neurocognitive test score was standardised using demographic-adjusted normative means of US 
origin (predominantly Caucasian ethnicity) to give a z-score.22 23 This was adjusted for age, and level of 
education for the colour trail scores, and age alone for the grooved pegboard scores.  
The z-scores for each hand on the grooved pegboard were averaged, and then combined with the z-
scores for the colour trail 1 and colour trail 2 tests to give an average z-score (NPZ-3 score) at each 
assessment .24   
Normative means for the grooved pegboard data were not available for participants <18 years so they 
were excluded from analyses. On-site monitoring identified concerns over the procedures used during 
baseline testing at one site (one out of the 8 sites in Uganda) so this site was excluded from primary 
analyses, but included in a sensitivity analysis. 
 
Statistical Analysis 
We assessed the influence of the following risk factors on NPZ-3 scores at first-line failure: age, sex, 
weight, BMI, ART history, viral load, CD4, WHO stage, history of CNS disease, family history of 
cardiovascular disease, diabetes, alcohol exposure, smoke exposure, haemoglobin, creatinine, social 
economic factors (availability of food, years of education, employment status, household monthly 
income), and concomitant medication.  
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Years on first-line ART and creatinine were truncated at approximate 99th percentiles (to avoid undue 
influence of extreme outliers on the estimated associations). At baseline, the unadjusted association 
between NPZ-3 score and each factor was modelled using complete case univariable linear regression 
with continuous factors modelled using fractional polynomials (FP) to allow for non-linear relationships 
with NPZ-3 score. Factors with univariable p<0.2 were included in a multivariable linear regression which 
used backward selection (exit criteria p=0.1) to select independent risk factors using multiple FPs to 
allow for non-linear relationships. In the multivariable analysis multiple imputation using Stata’s mi 
impute command (25 imputations) was used to account for missing risk factor data and missing test 
times where at least 2 of the 4 test times were known. Sensitivity analyses used only complete cases, or 
colour trail norms from an African-American population, or colour trail and grooved pegboard means 
from an HIV-negative Ugandan population.25 
Mean change in NPZ-3 scores from baseline were compared between the 3 treatment arms at weeks 48 
and 96 using t-tests and ANOVA; generalized estimating equations (GEE) (independent correlation 
structure with robust variance, normal distribution) were used to test differences between arms across 
all weeks.  
GEE (independent correlation structure with robust variance, normal distribution) were also used to 
investigate the effect of the factors selected in the baseline model on NPZ-3 scores at weeks 48 and 96 
(complete cases only), where possible time-updated factors were used. 
Statistical tests presented are two-sided. All analyses were carried out in Stata® version 13.1.   
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Results 
A total of 1277 individuals were enrolled into the EARNEST trial and randomized across the 3 treatment 
arms. Analysis of the main trial primary outcome (good disease control at week 96) demonstrated that 
PI/RAL was not superior to boosted PI/NRTI (p=0.21) but was non-inferior. PI-mono was not non-inferior 
to boosted PI/NRTI, and the arm was discontinued after week 96 due to markedly lower viral 
suppression and increased risk of the emergence of resistance mutations. Baseline characteristics and 
other outcomes across the 3 study arms were similar and are described elsewhere.14 
Of the 1156 evaluable participants at first-line failure (excluding 74 aged <18 years and 47 from the 
single site with implementation inconsistencies), 1036 (90%) had valid results for all 3 neurocognitive 
test domains (supplementary table 1). The main reasons for invalid tests were illiteracy (n=102 tests) 
and poor vision (n=51 tests) (supplementary table 2). The mean±sd z-score for colour trails 1 and 2 were 
-3.72±2.37, and -2.73±2.16 respectively, and for the combined pegboard z-score was -2.63±2.20 
(supplementary table 3).  
Factors Associated with neurocognitive function at Baseline 
The mean±sd NPZ-3 score at first-line failure was -2.96±1.74. Tables 1 and 2 show the unadjusted 
univariable and adjusted multivariable associations with NPZ-3 score at first-line failure respectively.  
In the adjusted multivariable model (Table 2), NPZ-3 scores at first-line failure were significantly lower in 
patients who were older (change in Z-score per 10 years older -0.25 (95% CI -0.35,-0.14) p<0.0001), had 
lower body weight (per 10 kg heavier +0.12 (0.02,0.21) p=0.01), higher viral loads (per doubling -0.07 (-
0.12,-0.03) p=0.002), lower hemoglobin (per 1mg/dl higher +0.16 (+0.11,+0.21) p<0.0001), fewer years 
of education (per doubling +0.39 (+0.26,+0.52) p<0.0001), worked fewer hours per week (per 10 hours 
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longer +0.09 (+0.05,+0.14) p<0.0001), had a previous CNS disease (-0.45 (-0.82,-0.08) p=0.02), or had 
taken fluconazole in the last 10 weeks (-0.61 (-0.99,-0.22) p=0.002).  
There was a trend towards NPZ-3 scores also being lower in those with lower CD4 cell count (per 100 
cells/mm3 higher +0.10 (-0.00, +0.21) p=0.06), lower household monthly income (vs <$50: $50-$200 
+0.29 (+0.03, +0.54); >$200 +0.21(-0.15, +0.56); p=0.08), and not taking dapsone in the last 10 weeks 
(+0.55 (-0.09, +1.19) p=0.09). 
Significant unadjusted effects of prior ART exposure, availability of regular meals, employment status, 
and other concomitant medication were no longer independent predictors after adjusting for the 
characteristics above. 
All sensitivity analyses gave broadly comparable results (supplementary tables 4-8). 
Neurocognitive Response to Treatment 
Overall, the NPZ-3 score increased on second-line therapy with a mean±SE change across all three study 
arms of +0.91±0.04 and +1.23±0.04 at week 48 and week 96 respectively (P<0.001). There was no 
statistically significant difference between the second-line regimens (Table 3 and Figures 1a and 1b) 
(p>0.2).  
At week 48 and 96, NPZ-3 scores were no longer associated with viral load (current viral load p=0.69, 
viral load at failure p=0.38), years of education at failure (p=0.19), current hours worked per week 
(p=0.20), CNS disease prior to current time (p=0.70), fluconazole use prior to current time (p=0.70), or 
taking dapsone in the 10 weeks before failure (p=0.55) but remained associated (p<0.05) with all other 
factors that were significantly related to baseline function as listed above (supplementary table 9). 
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Discussion  
In this analysis of a large second-line ART trial in Africa, we report reduced neurocognitive function 
scores among individuals failing first-line therapy. The scores were significantly lower in patients who 
were older, had lower body weight, higher viral load, lower haemoglobin, fewer years of education, 
fewer working hours, previous CNS disease, and who were taking fluconazole. Neurocognitive function 
improved after starting second-line ART with no significant difference observed between the 3 study 
arms.  
The very low z-scores we observed in our patients may in part be a function of the norms used for 
adjustment that were derived from a healthy, mostly Caucasian, American population. The same 
American normative datasets have been shown to produce inadequate adjustment of neurocognitive 
function in African HIV-positive patients living in the UK and the limitations may be even greater for our 
trial population.26 In a sensitivity analysis, we normalized results using a small dataset of HIV negative 
individuals from Uganda (Supplementary Table 7), and found that evidence of neurocognitive 
impairment persisted but the magnitude of this effect was reduced markedly.27 Although different 
normative datasets will generate different relative levels of impairment, the comparison with Ugandan 
norms together with the independent associations between scores at first-line failure and multiple HIV 
disease-related factors regardless of normative data used suggest that much of this impairment is likely 
to be genuine.  
Similar to most other studies, we observed that lower NPZ-3 scores were associated with higher viral 
loads at first-line failure after adjusting for other factors.28,29 HIV is a neurotropic virus that has both 
direct and indirect pathogenic effects on the CNS, and patients failing first-line ART in Africa often have 
very high viral loads (in the peripheral circulation but also possibly in the CNS) due to late detection of 
treatment failure because monitoring is largely clinical and immunological with no routine HIV viral load 
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monitoring. We also found a weak association at first-line failure between CD4 count and NPZ-3 score 
independent of viral load. It is noteworthy that patients with a previous CNS disease had lower NPZ-3 
scores at first-line failure. CNS diseases are a very common manifestation of HIV disease in Africa. 
Infections like cryptococcal meningitis not only cause considerable mortality in these settings, but can 
also leave critical damage to the CNS. We observed that taking fluconazole was an independent 
predictor of lower neurocognitive function even after adjusting for previous CNS disease. It could be 
that patients taking fluconazole were generally sicker in a variety of ways than those who were not 
taking this medication. These multiple disease-related associations indicate that the cause of severe 
neurocognitive impairment is likely multifactorial, in keeping with the heterogeneity of patients’ clinical 
condition at the time of first-line failure.  
The study also found a strong independent association between age as well as years of education and 
NPZ-3 scores among patients failing first-line ART. These factors are well known to influence 
neurocognitive function which is why neurocognitive data are usually presented as z-scores that attempt 
to adjust for these factors. The residual associations we have observed are likely to represent 
incomplete adjustment. Although the colour trail tests were adjusted for age and education level, the 
pegboard scores were adjusted for age only.  
Our study additionally provides the first substantive data on the changes in neurocognitive function on 
second-line therapy in a large population. We found evidence of improvement in neurocognitive 
function 48 weeks after starting second-line therapy which continued to week 96. This indicates that at 
least some of the excess impairment associated with first-line failure is likely to be reversible and is a 
further illustration of the clinical benefits (aside from avoidance of death and opportunistic infections) 
that may accrue from starting patients with ART failure on second-line therapy.  
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The similarity of the improvement of neurocognitive function across the three study arms is surprising 
for several reasons. Firstly, the PI-mono arm had markedly worse systemic virologic suppression rates, 
which has been associated with progression of CNS disease.30 Secondly, the two combination arms had 
greater CNS penetration effectiveness (CPE) score than the PI-mono arm (PI/NRTI combined score of 6, 
based on TDF/3TC as the commonest NRTI selection; PI/RAL combined score of 6 ; PI-mono score of 3) 
often considered to be related to neurocognitive outcomes.31 Although superior neurocognitive 
recovery might have been expected in the NRTI-containing arm given that CNS penetration of this class 
is well established, most of the patients in this arm were taking lamivudine with tenofovir which has the 
lowest CPE in this class. Raltegravir and lopinavir have similarly good CPE scores and we would therefore 
have expected an improved NC response in the arm in which they were combined.  
The similar response in the 3 arms suggests that the general response to ART (including recovery in 
general health, recovery from opportunistic infections, and improvement in mental status and 
nutritional status) rather than CNS drug penetration is the key determinant of neurocognitive function 
among patients on ART. The longitudinal changes in neurocognitive function and comparisons across 
study arms are likely to be reliable, less dependent on the validity of normative data described above.  
Additional possible limitations of this study are that we used a smaller test battery (3 domains) and it is 
possible that a more comprehensive battery might have given a different picture. Because key function 
domains such as learning and memory were not explored, we cannot tell whether the observed 
recovery with second-line is limited to the motor domains with possible persistence or even progression 
of poor performance on other cognitive function domains. However, pragmatic considerations made use 
of a more comprehensive neurocognitive test battery impossible given the scale of the study with over 
1000 patients tested on repeat occasions, located across a diversity of sites and challenging settings.  
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We have shown that this short battery of well-established tests can detect changes in response to 
therapy.  
Moreover, this test battery was performed by non-specialists and has the potential to be rolled out in 
real world settings to document prospective NCI changes on ART. As with all such studies, we cannot 
exclude the possibility that practice effects contributed to the some of the observed improvements in 
neurocognitive function over time. However, an HIV clinical trial in clinically stable patients that applied 
a similar brief battery of tests at annual intervals found an increase in NPZ-5 score of 0.53 after 3-5 years 
follow-up,32 and a similarly modest change (NPZ-5 increase of 0.13) was observed in a trial that re-tested 
stable patients with a similar battery after 6 months.33 Thus it is unlikely that practice effects alone 
would explain the magnitude of change in neurocognitive function (increase in NPZ-3 score of 1.2 over 
96 weeks) that we observed. Lastly, we did not systematically evaluate participants for depression and 
therefore did not determine its influence on neurocognitive function test results.34  
In summary, our study suggests that neurocognitive function is reduced among individuals failing first-
line HAART. We documented improvements in neurocognitive function that occur on second-line ART 
irrespective of the antiretroviral regimens used in the study, suggesting that the penetration of drugs 
into the CNS may not be a primary consideration in selecting a second-line regimen. These findings may 
provide an additional justification for timely identification of first-line failure and switch to second-line 
therapy.  
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Table 1: Characteristics and unadjusted associations with NPZ-3 scores at first-line 
failure 
Characteristic 
Overall 
Difference in NPZ-3 Score at first-line 
failure 
a
 
(N=1036) Difference (95% CI) 
 
P value 
    
Demographics    
Female - n(%) 602 (58%) -0.19 (-0.41, +0.02) 0.08 
Age (years) - mean±sd
 
38±10 -0.11 (-0.22, +0.00) 
b
 0.05 
Anthropometric measures    
Weight (kg)  mean±sd 58.4±11.4 +0.26 (+0.17, +0.35) 
b 
<0.0001 
ART history    
Years on Combination ART mean±sd
 
4.3±2.0 -0.00 (-0.05, +0.05) 0.99 
Prior exposure n(%)    
 zidovudine 662 (64%) -0.40 (-0.62, -0.18) <0.0001 
 stavudine 664 (64%) +0.21 (-0.01, +0.43) 0.06 
 tenofovir 143 (14%) -0.17 (-0.48, +0.14) 0.27 
 nevirapine 904 (87%) -0.09 (-0.41, +0.22) 0.56 
 efavirenz 315 (30%) -0.00 (-0.23, +0.23) 0.98 
Virology    
Viral load copies/ml  
 
   
 median (IQR) 65189 (22151-186004) -0.10 (-0.15, -0.05) 
c 
<0.0001 
 n(%) >=100,000  412 (40%)   
Immunology    
CD4 cells/mm
3
 
 
   
 median (IQR) 73 (29-147) +0.18 (+0.07, +0.29) 
d
 
 
0.001 
 n(%) <100 629 (61%)   
Medical history    
WHO stage n(%)    
 Available 638   
 1/2 129 (20%) 0 
0.06  3 275 (43%) -0.03 (-0.40, +0.34) 
 4 234 (37%) -0.37 (-0.75, +0.01) 
CNS disease n(%) 88 (8%) -0.32 (-0.70, +0.06) 0.10 
CVD n/ total n(%) 69/1035 (7%) -0.12 (-0.55, +0.30) 0.57 
Diabetes n/ total n(%) 19/1033 (2%) -0.24 (-1.03, +0.55) 0.56 
Alcohol and Smoking    
Alcohol (units/week) median(IQR) 0 (0-0) +0.04 (-0.00, +0.08) 0.06 
Ever smoked n/total n(%) 159/1033 (15%) +0.17 (-0.12, +0.47) 0.25 
Laboratory test    
Haemoglobin (g/dl)  mean±sd 12.0±2.2 +0.19 (+0.15, +0.24) <0.0001 
Creatinine (mg/dl) 
 
mean±sd 
 
0.78±0.26 +0.09 (-0.32, +0.50) 0.67 
Socio-economic    
Regular meals available n/total n(%) 678/1033 (66%) +0.35 (+0.12, +0.57) 0.002 
Years of education  median (IQR) 
 
11 (7-13) +0.41 (+0.26, +0.56) 
c 
<0.0001 
Employment status n(%)    
 Available 1033   
 Full time 500 (48%) 0 
<0.0001 
 Part time/occasional work 205 (20%) -0.40 (-0.68, -0.12) 
 Full time student 31 (3%) +0.03 (-0.59, +0.65) 
 Unemployed- ill health 134 (13%) -0.95 (-1.28, -0.62) 
 Unemployed- no jobs 163 (16%) -0.39 (-0.69, -0.08) 
Hours worked per week  27.5±25.5 +0.14 (+0.09, +0.18) 
b 
<0.0001 
Household monthly income n(%)    
 Available 921  
<0.0001 
 <$50 395 (43%) 0 
 $50-$200 338 (37%) +0.72 (+0.47, +0.96) 
 ≥$200 188 (20%) +0.85 (+0.56, +1.14) 
Concomitant medication in last 10 weeks     
Dapsone n(%) 26 (3%) +0.64 (-0.04, +1.32) 0.06 
Cotrimoxazole n(%) 952 (92%) -0.57 (-0.95, -0.18) 0.004 
Fluconazole n(%) 77 (7%) -0.76 (-1.16, -0.36) <0.0001 
Isoniazid n(%) 82 (8%) -0.46 (-0.85, -0.06) 0.02 
Ciprofloxin n(%) 36 (3%) -0.67 (-1.25, -0.10) 0.02 
Version 1 
Characteristic 
Overall 
Difference in NPZ-3 Score at first-line 
failure 
a
 
(N=1036) Difference (95% CI) 
 
P value 
Ethambutol n(%) 71 (7%) -0.51 (-0.93, -0.09) 0.02 
Pyrazinamid n(%) 61 (6%) -0.54 (-0.98, -0.09) 0.02 
Amoxycillin n(%) 40 (4%) -0.16 (-0.71, +0.39) 0.57 
P values from univariable linear regression of factor on NPZ-3 score on complete cases with fractional 
polynomials used to model continuous variables.  
a 
Difference given is difference in NPZ-3 score between groups or for a 1 unit increase unless specified 
b 
Difference in NPZ-3 score given for a 10 unit increase in the characteristic 
c 
Difference in NPZ-3 score given for a doubling in the characteristic 
d
 Difference in NPZ-3 score given for a 100 unit increase in the characteristic 
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Table 2: Multivariable associations with NPZ-3 score at first-line failure 
 
Characteristic 
Difference in NPZ-3 
score (95% CI) 
a 
P value 
 (N=1137)  
Age per 10 year older  -0.25 (-0.35, -0.14) <0.0001 
Weight per 10 kg heavier +0.12 (+0.02, +0.21) 0.01 
Viral load at failure per doubling
 
-0.07 (-0.12, -0.03) 0.002 
CD4 at failure per 100 cell higher +0.10 (-0.00, +0.21) 0.06 
Haemoglobin per 1 g/dl higher +0.16 (+0.11, +0.21) <0.0001 
Years of education per doubling
 
+0.39 (+0.26,+0.52) <0.0001 
Hours worked per week per 10 hours longer
 
+0.09 (+0.05, +0.14) <0.0001 
Household income  
0.08 
≤$50 0 
$50-$200 +0.29 (+0.03, +0.54) 
>$200 +0.21 (-0.15, +0.56) 
Previous CNS disease -0.45 (-0.82, -0.08) 0.02 
Fluconazole in the last 10 weeks
 
-0.61 (-0.99, -0.22) 0.002 
Dapsone in the last 10 weeks +0.55 (-0.09, +1.19) 0.09 
a
 Also adjusted for centre (p<0.0001). Multivariable linear regression based on 
multiple imputation, and allowing non-linearity using fractional polynomials. 
Factors selected based on backwards elimination from all Table 1 factors with 
p<0.2 (exit p=0.1), 
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Table 3: Changes in NPZ-3 score by second-line regimen 
 
 
PI/ NRTI 
N=390 
PI/ RAL 
N=389 
PI mono 
N=377 
Global 
P value 
PI/RAL vs PI/NRTI PI mono vs PI/NRTI 
 Difference (95% CI) p value 
Difference 
(95% CI) 
p value 
Week 0         
 Available 359 345 332      
 mean score ±sd -3.02±1.7 -2.92±1.8 -2.92±1.8      
Week 48         
 Available 324 315 304      
 mean change ±se +0.86±0.07 +0.95±0.07 +0.91±0.07 0.65 +0.09 (-0.10, +0.28) 0.34 +0.05 (-0.15, +0.24) 0.65 
Week 96         
 Available 311 306 298      
 mean change ±se +1.23±0.07 +1.28±0.07 +1.18±0.08 0.66 +0.05 (-0.16, +0.26) 0.65 -0.04 (-0.26, +0.16) 0.64 
Under 18 excluded from all analyses. P values from ANOVA and t-tests 
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Figure 1a: Mean absolute NPZ-3 score over time on second-line therapy 
 
Figure 1b: Mean change in NPZ-3 score over time on second-line therapy 
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Supplementary Table 1: Pattern of missing tests at first-line failure 
Pattern (1=test done, 0 =test missing) Frequency 
N=1156 
a 
Pegboard-d Pegboard-nd CT 1 CT2 
1 1 1 1 1036 
1 1 0 0 66 
1 1 1 0 23 
0 0 0 0 17 
1 1 0 1 4 
1 0 1 1 3 
0 0 1 1 3 
1 0 0 0 2 
1 0 1 0 1 
0 1 1 1 1 
a 
Excluding all tests from one site with implementation inconsistencies and patients 
who were under 18 at enrolment Pegboard-d: dominant hand; Pegboard-nd: non-
dominant hand; CT1: colour trails test 1; CT2: colour trails test 2   
  
Supplementary Table 2: Reasons for not completing neurocognitive tests at first-line 
failure 
  Total 
Total Randomised 1277 
Over 18 & not at 1 excluded site 1156 
Colour Trail 1  
Number of valid tests 1067 
Number of invalid tests 89 
 cannot read/write 51 
 made a mistake 10 
 physically not capable/ too ill 1 
 site problem/error 1 
 unable to complete 7 
 Vision 13 
 Other 1 
Colour Trail 2  
Number of valid tests 1047 
Number of invalid tests 109 
 cannot read/write 51 
 made a mistake 19 
 site problem/error 1 
 physically not capable/ too ill 6 
 unable to complete 13 
 Vision 17 
 Other 2 
Pegboard dominant  
Number of valid tests 1135 
Number of invalid tests 21 
 no reason given 1 
 physically not capable/ too ill 5 
 unable to complete 5 
 Vision 10 
Pegboard non-dominant  
Number of valid tests 1130 
Number of invalid tests 26 
 no reason given 1 
 physically not capable/ too ill 6 
 unable to complete 8 
 Vision 11 
 Supplementary Table 3: Test times and Z-scores at first-line failure 
 
Test 
N 
Time (sec) 
mean±sd 
Z-score  
mean±sd 
Overall score 1036  -2.95±1.74 
Colour trail 1 1067 102±50 -3.72±2.37 
Colour trail 2 1047 189±85 -2.73±2.16 
Mean pegboard 1129  -2.63±2.20 
 Pegboard dominant 1135 93±38 -2.99±2.48 
 Pegboard non-dominant 1130 100±45 -2.29±2.22 
Z-scores were truncated at -8 before calculating z-scoresmeans and then taking the mean of 
colours trails 1 and 2 z-scores and the mean pegboard z-score to form an overall composite z-
score 
  
Supplementary Table 4: Sensitivity analysis - complete cases multivariable risk 
factors at first-line failure 
 
Characteristic 
Adjusted 
Difference in NPZ-3 
score (95% CI)  P value 
 (N=983)  
Age per 10 year older -0.23 (-0.35, -0.12) <0.0001 
Weight per 10kg heavier +0.13 (0.03, +0.23) 0.01 
Viral load at failure per doubling
 
-0.07 (-0.11, -0.02) 0.01 
CD4 at failure per 100 cell higher +0.05 (-0.06, +0.16) 0.38 
Haemoglobin per g/dl higher +0.16 (+0.11, +0.22) <0.0001 
Years of education per doubling
 
+0.21 (+0.04, +0.38) 0.01 
Hours worked per week per 10 hour longer
 
+0.08 (+0.03, +0.13) 0.001 
Household income  
0.04 
≤$50 0 
$50-$200 +0.34 (+0.08, +0.61) 
>$200 +0.20 (-0.17, +0.56) 
Previous CNS disease -0.38 (-0.76, +0.01) 0.05 
Fluconazole in the last 10 weeks
 
-0.55 (-0.99, -0.10) 0.01 
Dapsone in the last 10 weeks +0.62 (-0.04, +1.27) 0.07 
Also adjusted for Centre p<0.0001. Multivariable linear regression based on 
complete cases, and allowing non-linearity using fractional polynomials. Factors 
selected based on backwards elimination from all Table 1 factors with p<0.2 
(exit p=0.1),  
  
Supplementary Table 5a: Sensitivity analysis - African American age adjusted 
colour trail z-scores 
 
Test 
N 
Z-score  
mean±sd 
Overall score 888 -3.13 ±1.8 
Colour trail 1 914 -4.38±3.8 
Colour trail 2 897 -3.48±3.2 
African American Age adjusted norms were limited to those ages 
between 20 and 50.  
 
 
Supplementary Table 5b: Sensitivity analysis- African American age adjusted 
colour trail z-scores multivariable risk factors at first-line failure 
 
 
Characteristic 
Adjusted 
Difference in NPZ-
3 score (95% CI)  P value 
 (N=973)  
Age per 10 year older -0.09 (-0.25, +0.06) 0.25 
Weight per 10kg heavier +0.09 (-0.01, +0.19) 0.09 
Viral load at failure per doubling
 
-0.08 (-0.13, -0.03) 0.002 
CD4 at failure per 100 cell higher +0.09 (-0.02, +0.20) 0.10 
Haemoglobin per g/dl higher +0.16 (+0.11, +0.21) <0.0001 
Years of education per doubling
 
+0.77 (+0.63, +0.90) <0.0001 
Hours worked per week per 10 hour longer
 
+0.08 (+0.03, +0.12) 0.001 
Household income  
0.004 
≤$50 0 
$50-$200 +0.43 (+0.15, +0.71) 
>$200 +0.48 (+0.09, +0.86) 
Previous CNS disease -0.69 (-1.09, -0.29) 0.001 
Fluconazole in the last 10 weeks
 
-0.42 (-0.82, -0.03) 0.04 
Dapsone in the last 10 weeks +0.33 (-0.33, +0.99) 0.33 
Adjusted for Centre p<0.0001. Multivariable linear regression based on 
multiple imputation and allowing non-linearity using fractional polynomials. 
Factors selected based on backwards elimination from all Table 1 factors with 
p<0.2 (exit p=0.1), 
Supplementary Table 6a: Sensitivity analysis - African American Education 
adjusted colour trail z-scores 
 
Test 
N 
Z-score  
mean±sd 
Overall score 1036 -3.18±1.8 
Colour trail 1 1067 -4.23±3.4 
Colour trail 2 1047 -3.50±2.9 
 
Supplementary Table 6b: Sensitivity analysis- African American Education 
adjusted colour trail z-scores multivariable risk factors at first-line failure  
 
 
Characteristic 
 Adjusted 
Difference in NPZ-
3 score (95% CI)  P value 
 (N=983)  
Age per 10 year older  -0.55 (-0.66, -0.45) <0.0001 
Weight per 10kg heavier +0.13 (+0.03, +0.22) 0.007 
Viral load at failure per doubling
 
-0.07 (-0.11, -0.03) 0.002 
CD4 at failure per 100 cell higher +0.09 (-0.01, +0.19) 0.07 
Haemoglobin per g/dl higher +0.14 (+0.10, +0.19) <0.0001 
Years of education per doubling
 
+0.69 (+0.56, +0.81) <0.0001 
Hours worked per week per 10 hour longer
 
+0.09 (+0.05, +0.13) <0.0001 
Household income  
0.02 
≤$50 0 
$50-$200 +0.34 (+0.09, +0.59) 
>$200 +0.36 (+0.02, +0.71) 
Previous CNS disease -0.45 (-0.80, -0.09) 0.01 
Fluconazole in the last 10 weeks
 
-0.48 (-0.86, -0.11) 0.01 
Dapsone in the last 10 weeks +0.52 (-0.11, +1.14) 0.11 
Adjusted for Centre p<0.0001. Multivariable linear regression based on 
multiple imputation and allowing non-linearity using fractional polynomials. 
Factors selected based on backwards elimination from all Table 1 factors with 
p<0.2 (exit p=0.1), 
Supplementary Table 7a: Sensitivity analysis – Ugandan norm z-scores 
 
Test 
N 
Z-score  
mean±sd 
Overall score 1036 -0.93±1.48 
Colour trail 1 1067 -1.25±2.25 
Colour trail 2 1047 -1.75±2.31 
Pegboard- dominant hand 1133 -0.31±1.79 
Pegboard- non-dominant hand 1130 +0.07±1.79 
 
Supplementary Table 7b: Sensitivity analysis- Ugandan norm z-scores 
multivariable risk factors at first-line failure  
 
Characteristic 
 Adjusted 
Difference in NPZ-
3 score (95% CI)  P value 
 (N=1137)  
Age per 10 year older  -0.04 (-0.05, -0.04) <0.0001 
Weight per 10kg heavier +0.11 (+0.04, +0.19) 0.004 
Viral load at failure per doubling
 
-0.07 (-0.11, -0.03) <0.0001 
CD4 at failure per 100 cell higher +0.08 (-0.01, +0.16) 0.08 
Haemoglobin per g/dl higher +0.11 (+0.07, +0.15) <0.0001 
Years of education per doubling
 
+0.66 (+0.55, +0.77) <0.0001 
Hours worked per week per 10 hour longer
 
+0.09 (+0.05, +0.12) <0.0001 
Household income  
0.04 
≤$50 0 
$50-$200 +0.25 (+0.4, +0.46) 
>$200 +0.27 (-0.01, +0.56) 
Previous CNS disease -0.45 (-0.75, -0.15) 0.003 
Fluconazole in the last 10 weeks
 
-0.32 (-0.64, 0.00) 0.05 
Dapsone in the last 10 weeks +0.50 (-0.02, +1.02) 0.06 
Adjusted for Centre p<0.0001. Multivariable linear regression based on 
multiple imputation and allowing non-linearity using fractional polynomials. 
Factors selected based on backwards elimination from all Table 1 factors with 
p<0.2 (exit p=0.1), 
 
 
Supplementary Table 7c: Sensitivity analysis- Ugandan norm z-scores changes in score by second–line regimen 
 
 
PI/ NRTI 
N=390 
PI/ RAL 
N=389 
PI mono 
N=377 
Global 
P value 
PI/RAL vs PI/NRTI PI mono vs PI/NRTI 
 Difference (95% CI) p value 
Difference 
(95% CI) 
p value 
Week 0         
 Available 359 345 332      
 mean score ±sd -0.98±1.45  -0.88±1.51 -0.92±1.50      
Week 48         
 Available 324 315 304      
 mean change ±se +0.60±0.05 +0.62±0.05 +0.60±0.06 0.96 0.02 (-0.13, +0.16) 0.84 -0.00 (-0.16, +0.15) 0.96 
Week 96         
 Available 311 306 298      
 mean change ±se +0.81±0.06 +0.80±0.06 +0.75±0.06 0.76 -0.00 (-0.17, +0.16) 0.95 -0.06 (-0.23, +0.11) 0.51 
Under 18 excluded from all analyses. P values from ANOVA and t-tests 
 
Supplementary Figure 1: Sensitivity analysis- Ugandan norm z-scores over 
time on second–line therapy 
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Supplementary Table 8: Sensitivity analysis - Including site with 
implementation inconsistencies multivariable risk factors at first-line failure 
 
 
 
 
Characteristic 
Adjusted 
Difference in NPZ-
3 score (95% CI)  P value 
 (N=983)  
Age per 10 year older -0.25 (-0.36, -0.15) <0.0001 
Weight per 10kg heavier +0.12 (+0.02, +0.21) 0.02 
Viral load at failure per doubling
 
-0.07 (-0.11, -0.02) 0.004 
CD4 at failure per 100 cell higher +0.10 (-0.01, +0.20) 0.08 
Haemoglobin per g/dl higher +0.16 (+0.11, +0.21) <0.0001 
Years of education per doubling
 
+0.40 (+0.27, +0.52) <0.0001 
Hours worked per week per 10 hour longer
 
+0.09 (+0.05, +0.13) <0.0001 
Household income  
0.10 
≤$50 0 
$50-$200 +0.27 (+0.02, +0.55) 
>$200 +0.20 (-0.15, +0.55) 
Previous CNS disease -0.46 (-0.83, -0.09) 0.01 
Fluconazole in the last 10 weeks
 
-0.58 (-0.96, -0.19) 0.003 
Dapsone in the last 10 weeks +0.46 (-0.15, +1.08) 0.14 
Adjusted for Centre p<0.0001. Multivariable linear regression based on 
multiple imputation and allowing non-linearity using fractional polynomials. 
Factors selected based on backwards elimination from all Table 1 factors with 
p<0.2 (exit p=0.1), 
 
 
  
Supplementary Table 9: Multivariable Risk factors associated with NPZ-3 score at week 
48 and 96 
 
Characteristic  
Adjusted 
difference in NPZ-3 
score (95% CI) 
 
P value 
 (N=830)  
Baseline NPZ-3 score +0.57 (+0.52, +0.61) <0.001 
Weeks on second-line ART  0.02 
48 weeks 0 
96 weeks +0.38 (+0.07, +0.69) 
Age at failure per 10 year older -0.12 (-0.20, -0.04) 0.003 
Weight at current time per 10 kg heavier +0.06 (-0.00, +0.11) 0.05 
Viral load per doubling
 
  
At failure  +0.01 (-0.02, +0.04) 0.38 
At current time +0.00 (-0.02, +0.02) 0.69 
CD4 per 100 cell higher   
At failure  -0.01 (-0.07, +0.05) 0.84 
Change in CD4 from failure to current time  +0.08 (+0.04, +0.13) <0.0001 
Haemoglobin at current time per g/dl higher +0.04 (+0.00, +0.07) 0.03 
Years of education at failure per doubling
 
+0.07 (-0.03,+0.18) 0.19 
Hours worked per week at current time per 10 hour 
longer
 +0.02 (-0.01, +0.04) 0.20 
household income at current time   
≤$50 0 0.04 
$50-$200 +0.17 (+0.01, +0.33) 
>$200 +0.25 (+0.05, +0.46) 
CNS disease prior to current time -0.05 (-0.30, +0.20) 0.70 
Fluconazole use prior to current time
 
-0.05 (-0.29, +0.19) 0.70 
Dapsone use in the 10 weeks before failure +0.11 (-0.26, +0.49) 0.55 
Adjusted for Centre (p<0.0001). Model of change in NPZ-3 scores from baseline to week 48 
and 96 using generalised estimating equations with an independent working correlation 
structure and robust variance estimators. Based on complete cases and allowing non-
linearity using fractional polynomials. 
 
 
